Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $2.7 in the prior trading day, ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) closed at $2.57, down -4.81%. In other words, the price has decreased by -$4.81 from its previous closing price. On the day, 2.3 million shares were traded. IPA stock price reached its highest trading level at $2.9 during the session, while it also had its lowest trading level at $2.51.
Ratios:
Our goal is to gain a better understanding of IPA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.85 and its Current Ratio is at 2.08. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.49.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 02, 2022, initiated with a Buy rating and assigned the stock a target price of $9.
On October 25, 2021, The Benchmark Company started tracking the stock assigning a Buy rating and target price of $12.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IPA now has a Market Capitalization of 118616032 and an Enterprise Value of 127354120. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.75 while its Price-to-Book (P/B) ratio in mrq is 6.93. Its current Enterprise Value per Revenue stands at 5.194 whereas that against EBITDA is -13.676.
Stock Price History:
The Beta on a monthly basis for IPA is 0.50, which has changed by 1.8876405 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, IPA has reached a high of $2.72, while it has fallen to a 52-week low of $0.27. The 50-Day Moving Average of the stock is 65.81%, while the 200-Day Moving Average is calculated to be 255.83%.
Shares Statistics:
The stock has traded on average 2.65M shares per day over the past 3-months and 1882060 shares per day over the last 10 days, according to various share statistics. A total of 46.15M shares are outstanding, with a floating share count of 40.01M. Insiders hold about 13.31% of the company’s shares, while institutions hold 8.67% stake in the company. Shares short for IPA as of 1753920000 were 725308 with a Short Ratio of 0.27, compared to 1751241600 on 231139. Therefore, it implies a Short% of Shares Outstanding of 725308 and a Short% of Float of 1.59.
Earnings Estimates
ImmunoPrecise Antibodies Ltd (IPA) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.01 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.04 and -$0.18 for the fiscal current year, implying an average EPS of -$0.11. EPS for the following year is $0.04, with 1.0 analysts recommending between $0.04 and $0.04.
Revenue Estimates
2 analysts predict $5.9M in revenue for the current quarter. It ranges from a high estimate of $6.1M to a low estimate of $5.7M. As of the current estimate, ImmunoPrecise Antibodies Ltd’s year-ago sales were $5.26MFor the next quarter, 2 analysts are estimating revenue of $7.25M. There is a high estimate of $7.9M for the next quarter, whereas the lowest estimate is $6.6M.
A total of 2 analysts have provided revenue estimates for IPA’s current fiscal year. The highest revenue estimate was $31.06M, while the lowest revenue estimate was $26.6M, resulting in an average revenue estimate of $28.83M. In the same quarter a year ago, actual revenue was $24.52MBased on 1 analysts’ estimates, the company’s revenue will be $38.1M in the next fiscal year. The high estimate is $38.1M and the low estimate is $38.1M.
